Current Treatment Options in Gastroenterology

, Volume 9, Issue 1, pp 23–37 | Cite as

Diarrhea in patients with AIDS

  • Susan C. Morpeth
  • Nathan M. Thielman
Article

Opinion statement

Diarrhea in patients with AIDS is a worldwide problem that can have a devastating impact on quality of life for the patient. Chronic diarrhea, usually defined as at least 4 weeks’ duration, is more common in patients with low CD4-positive T-lymphocyte counts, signaling advanced immunosuppression. Some organisms, such as Microsporidia, usually cause diarrhea only in the immunosuppressed; others, such as Cryptosporidium, Salmonella, Shigella, and Campylobacter, which are capable of causing diarrhea in the immunocompetent population, produce more severe or prolonged infections in people living with AIDS. Familiarity with the most common pathogens in the clinician’s region will help with diagnosis and treatment. Because treatment options vary widely depending upon the infectious agent, thorough microbiologic evaluation is warranted. A stepped diagnostic approach of stool cultures and specialized microscopy and stains for protozoa, followed by sigmoidoscopy or colonoscopy and duodenoscopy with biopsies for histopathological examination is recommended in all patients with persistent, disabling diarrhea who have a CD4 count of less than 200/mm3, and should be considered for those with higher counts on an individual basis. Treatment, tailored to the specific pathogen, may need to be prolonged in the most severely immunocompromised patients to prevent relapse or recrudescence. For patients taking antiretroviral therapy (especially protease inhibitors) in whom no infectious agent can be found, diarrhea may be due to the medications. Nonspecific antidiarrheal agents should be tried until one that suits the patient is found. The most essential component of any therapeutic strategy for a patient with AIDS-associated diarrhea is restoration of the underlying immunologic defect using highly active antiretroviral therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Tramarin A, Parise N, Campostrini S, et al.: Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004, 13: 243–250.PubMedCrossRefGoogle Scholar
  2. 2.
    Weber R, Ledergerber B, Zbinden R, et al.: Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Arch Intern Med 1999, 159: 1473–1480.PubMedCrossRefGoogle Scholar
  3. 3.
    Brink AK, Mahe C, Watera C, et al.: Diarrhea, CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. J Infect 2002, 45: 99–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Ole-Nguyaine S, Crump J, Kibiki G, et al.: HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol 2004, 98: 171–179.PubMedCrossRefGoogle Scholar
  5. 5.
    Groenewald P, Nannan N, Bourne D, et al.: Identifying deaths from AIDS in South Africa. AIDS 2005, 19: 193–201.PubMedCrossRefGoogle Scholar
  6. 6.
    Trout H, Mentre F, Panhard X, et al.: Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004, 48: 538–545.PubMedCrossRefGoogle Scholar
  7. 7.
    Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004, 38: 280–283.PubMedCrossRefGoogle Scholar
  8. 8.
    Bushen O, Davenport J, Lima A, et al.: Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin Infect Dis 2004, 38: 1764–1770.PubMedCrossRefGoogle Scholar
  9. 9.
    Smith P, Janoff E: Gastrointestinal infections in HIV-1 disease. In Infections of the Gastrointestinal Tract, edn 2. Edited by Blaser MJ, Smith PD, Ravdin JI, et al. Philadelphia: Lippincott Williams & Wilkins; 2002: 415–443. This book chapter concentrates on gastrointestinal infections of both the upper and lower gastrointestinal tract in HIV disease and is a good up-to-date review of the topic.Google Scholar
  10. 10.
    Keating J, Bjarnason I, Somasundaram S, et al.: Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea. Gut 1995, 37: 623–629.PubMedGoogle Scholar
  11. 11.
    Sharpstone D, Neild P, Crane R, et al.: Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999, 45: 70–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Pernet P, Vittecoq D, Kodjo A, et al.: Intestinal absorption and permeability in human immunodeficiency virusinfected patients. Scand J Gastroenterol 1999, 34: 29–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Bini EJ, Cohen J: Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected patients with chronic diarrhea. Am J Gastroenterol 1999, 94: 3553–3559.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen J, West A, Bini E: Infectious diarrhea in human immunodeficiency virus [review]. Gastroenterol Clin North Am 2001, 30: 637–664.PubMedCrossRefGoogle Scholar
  15. 15.
    Kelly P, Lungu F, Keane E, et al.: Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. Br Med J 1996, 312: 1187–1191.Google Scholar
  16. 16.
    Kearney DJ, Steuerwald M, Koch J, Cello JP: A prospective study of endoscopy in HIV-associated diarrhea. Am J Gastroenterol 1999, 94: 596–602.PubMedCrossRefGoogle Scholar
  17. 17.
    Dieterich DT, Rahmin M: Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991, 4(Suppl 1): S29-S35.PubMedGoogle Scholar
  18. 18.
    Blanshard C, Francis N, Gazzard BG: Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients. Gut 1996, 39: 824–832. This British study took 155 patients with AIDS, a CD4 count of less than 200/mm3, and chronic diarrhea and prospectively followed them during and after extensive work-up and treatment of diagnosed pathogens. At least one potential pathogen was found in 83% of patients. A decision-tree analysis was performed, and the authors propose a very reasonable approach to investigating immunosuppressed patients with AIDS.PubMedGoogle Scholar
  19. 19.
    Cranston RD, Anton PA, McGowan IM: Gastrointestinal mucosal biopsy in HIV disease and AIDS [review]. Gastrointest Endosc Clin N Am 2000, 10: 637–667, vi.PubMedGoogle Scholar
  20. 20.
    Anastasi JK, Capili B: HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control 2000, 28: 262–266.PubMedCrossRefGoogle Scholar
  21. 21.
    Germani Y, Minssart P, Vohito M, et al.: Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg 1998, 59: 1008–1014.PubMedGoogle Scholar
  22. 22.
    Carr A, Marriott D, Field A, et al.: Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998, 351: 256–261.PubMedCrossRefGoogle Scholar
  23. 23.
    Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 2004, 53(RR-15):1-112. This recent report from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious Diseases Society of America is an excellent resource for all clinicians treating patients with AIDS. It covers many opportunistic infections and provides treatment recommendations with annotations showing the strength of the evidence for each recommendation.Google Scholar
  24. 24.
    Sherman DS, Fish DN: Management of protease inhibitor-associated diarrhea. Clin Infect Dis 2000, 30: 908–914. This is an excellent overview of the management of proteaseinhibitor-related diarrhea, including the use of available overthe-counter products.PubMedCrossRefGoogle Scholar
  25. 25.
    Bode H, Schmidt W, Schulzke JD, et al.: Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6. Ann N Y Acad Sci 2000, 915: 117–122.PubMedCrossRefGoogle Scholar
  26. 26.
    Villamor E, Mbise R, Spiegelman D, et al.: Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth. Pediatrics 2002, 109: E6.PubMedCrossRefGoogle Scholar
  27. 27.
    Fawzi WW, Msamanga GI, Wei R, et al.: Effect of providing vitamin supplements to human immunodeficiency virus-infected, lactating mothers on the child’s morbidity and CD4+ cell counts. Clin Infect Dis 2003, 36: 1053–1062.PubMedCrossRefGoogle Scholar
  28. 28.
    Kelly P, Musonda R, Kafwembe E, et al.: Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial. AIDS 1999, 13: 495–500.PubMedCrossRefGoogle Scholar
  29. 29.
    Hayes C, Elliot E, Krales E, Downer G: Food and water safety for persons infected with human immunodeficiency virus. Clin Infect Dis 2003, 36: S106-S109.PubMedCrossRefGoogle Scholar
  30. 30.
    Hoge C, Gambel J, Srijan A, Echeverria P: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998, 26: 341–345.PubMedGoogle Scholar
  31. 31.
    Wanke C, Gerrior J, Blais V, et al.: Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J Infect Dis 1998, 178: 1369–1372.PubMedCrossRefGoogle Scholar
  32. 32.
    Mossoro C, Glaziou P, Yassibanda S, et al.: Chronic diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome associated with HEp-2 adherent Escherichia coli in adults infected with human immunodeficiency virus in Bangui, Central African Republic. J Clin Microbiol 2002, 40: 3086–3088.PubMedCrossRefGoogle Scholar
  33. 33.
    Verdier RI, Fitzgerald DW, Johnson WD, Jr, Pape JW: Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000, 132: 885–888.PubMedGoogle Scholar
  34. 34.
    Fleming T, ed: Red Book, Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson PDR; 2005.Google Scholar
  35. 35.
    Mermin J, Lule J, Ekwaru J, et al.: Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364: 1428–1434.PubMedCrossRefGoogle Scholar
  36. 36.
    Drugs for parasitic infections. Med Lett Drugs Ther 2004, 46:1189.Google Scholar
  37. 37.
    Engberg J, Aarestrup FM, Taylor DE, et al.: Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001, 7: 24–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Ward TT, Rimland D, Kauffman C, et al.: Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998, 27: 1278–1285.PubMedGoogle Scholar
  39. 39.
    Dunne M, Fessel J, Kumar P, et al.: A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000, 31: 1245–1252.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith NH, Cron S, Valdez LM, et al.: Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis 1998, 178: 900–903.PubMedGoogle Scholar
  41. 41.
    Kadappu KK, Nagaraja MV, Rao PV, Shastry BA: Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad Med 2002, 48: 179–181.PubMedGoogle Scholar
  42. 42.
    Treating opportunistic infections among HIV-exposed and infected children. MMWR Morb Mortal Wkly Rep 2004, 53(RR-14):1-63. This is an up-to-date guideline providing recommendations from the CDC, the National Institutes of Health, and the Infectious Diseases Society of America for treating children with AIDS-related opportunistic infections.Google Scholar
  43. 43.
    Lu SS, Schwartz JM, Simon DM, Brandt LJ: Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 1994, 89: 1226–1229.PubMedGoogle Scholar
  44. 44.
    Pelaez T, Alcala L, Alonso R, et al.: Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46: 1647–1650.PubMedCrossRefGoogle Scholar
  45. 45.
    Rossignol JF, Hidalgo H, Feregrino M, et al.: A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998, 92: 663–666.PubMedCrossRefGoogle Scholar
  46. 46.
    Zulu I, Kelly P, Njobvu L, et al.: Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial. Aliment Pharmacol Ther 2005, 21: 757–763.PubMedCrossRefGoogle Scholar
  47. 47.
    Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005, 40: 1173–1180.PubMedCrossRefGoogle Scholar
  48. 48.
    Giacometti A, Cirioni O, Barchiesi F, et al.: Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 2000, 45: 453–456.PubMedCrossRefGoogle Scholar
  49. 49.
    White AC,Jr, Chappell CL, Hayat CS, et al.: Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994, 170: 419–424.PubMedGoogle Scholar
  50. 50.
    Hewitt RG, Yiannoutsos CT, Higgs ES, et al.: Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 2000, 31: 1084–1092.PubMedCrossRefGoogle Scholar
  51. 51.
    Zulu I, Veitch A, Sianongo S, et al.: Albendazole chemotherapy for AIDS-related diarrhoea in Zambia-clinical, parasitological and mucosal responses. Aliment Pharmacol Ther 2002, 16: 595–601.PubMedCrossRefGoogle Scholar
  52. 52.
    Dieterich DT, Lew EA, Kotler DP, et al.: Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994, 169: 178–183.PubMedGoogle Scholar
  53. 53.
    Molina JM, Chastang C, Goguel J, et al.: Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998, 177: 1373–1377.PubMedGoogle Scholar
  54. 54.
    Conteas C, Berlin G, Ash L, Pruthi J: Therapy for human gastrointestinal microsporidiosis. Am J Trop Med Hyg 2000, 63: 121–127.PubMedGoogle Scholar
  55. 55.
    Molina J, Tourneur M, Sarfati C, et al.: Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002, 346: 1963–1969.PubMedCrossRefGoogle Scholar
  56. 56.
    Conteas C, Berlin O, Speck C, et al.: Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998, 58: 555–558.PubMedGoogle Scholar
  57. 57.
    Dieterich DT, Kotler DP, Busch DF, et al.: Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 1993, 167: 278–282.PubMedGoogle Scholar
  58. 58.
    Blanshard C, Benhamou Y, Dohin E, et al.: Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995, 172: 622–628.PubMedGoogle Scholar
  59. 59.
    Squires KE: Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. AIDS 1996, 10(Suppl 4): S13-S18.PubMedGoogle Scholar
  60. 60.
    Martin DF, Sierra-Madero J, Walmsley S, et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002, 346: 1119–1126.PubMedCrossRefGoogle Scholar
  61. 61.
    Jabs DA, Enger C, Forman M, Dunn JP: Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother 1998, 42: 2240–2244.PubMedGoogle Scholar
  62. 62.
    Jabs DA, Enger C, Dunn JP, Forman M: Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998, 177: 770–773.PubMedGoogle Scholar
  63. 63.
    Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, et al.: Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 1994, 8: 1563–1567.PubMedCrossRefGoogle Scholar
  64. 64.
    Simon DM, Cello JP, Valenzuela J, et al.: Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995, 108: 1753–1760.PubMedCrossRefGoogle Scholar
  65. 65.
    Palmer K, Corbett C, Holdsworth C: Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980, 79: 1272–1275.PubMedGoogle Scholar
  66. 66.
    Didier E: Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob Agents Chemother 1997, 41: 1541–1546.PubMedGoogle Scholar
  67. 67.
    Coyle C, Kent M, Tanowitz H, et al.: TNP-470 is an effective antimicrosporidial agent. J Infect Dis 1998, 177: 515–518.PubMedCrossRefGoogle Scholar
  68. 68.
    Sobottka I, Bartscht K, Schafer P, et al.: In vitro activity of polyoxin D and nikkomycin Z against Encephalitozoon cuniculi. Parasitol Res 2002, 88: 451–453.PubMedCrossRefGoogle Scholar
  69. 69.
    Bacchi C, Weiss L, Lane S, et al.: Novel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infection. Antimicrob Agents Chemother 2002, 46: 55–61.PubMedCrossRefGoogle Scholar
  70. 70.
    Price D, Schmid M, Ong E, et al.: Pancreatic exocrine insufficiency in HIV-positive patients. HIV Med 2005, 6: 33–36.PubMedCrossRefGoogle Scholar
  71. 71.
    Wignot TM, Stewart RP, Schray KJ, et al.: In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes. Pharm Res 2004, 21: 420–427.PubMedCrossRefGoogle Scholar
  72. 72.
    Holodniy M, Koch J, Mistal M, et al.: A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999, 94: 3267–3273.PubMedCrossRefGoogle Scholar
  73. 73.
    Huffman F, Walgren M: L-glutamine supplementation improves nelfinavir-associated diarrhea in HIVinfected individuals. HIV Clin Trials 2003, 4: 324–329.PubMedCrossRefGoogle Scholar
  74. 74.
    Jensen-Fangel S, Justesen US, Black FT, et al.: The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients. HIV Med 2003, 4: 48–52.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Susan C. Morpeth
    • 1
  • Nathan M. Thielman
  1. 1.Division of Infectious Diseases and International HealthDuke University Medical CenterDurhamUSA

Personalised recommendations